Novo Nordisk
Novo Nordisk Performance
Day Range
- Low $103
- High $105.74
52 Week Range
- Low $94.73
- High $148.15
- Open Price $103.43
- Previous Close $102.63
- Volume 7509744
Novo Nordisk Share Price
- 1 Day + 2.57%
- 1 Week -1.67%
- 1 Month -10.86%
- 3 Months -22.17%
- 6 Months -20.18%
- 1 Year + 3.83%
- 3 Year + 84.87%
Novo Nordisk Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 3
- Bearish Moving Average
- ___
- 13
Novo Nordisk Resistance and Support
| Resistance | |
|---|---|
| First Resistance | $106.34 |
| Second Resistance | $107.41 |
| Third Resistance | $109.08 |
| RSI | 39.43 |
| MFI | 43.93 |
| MACD Single Line | -3.99 |
| MACD | -3.89 |
| Support | |
|---|---|
| First Support | $103.60 |
| Second Support | $101.93 |
| Third Support | $100.86 |
Know more about Novo Nordisk
Novo Nordisk A/S was founded in 1923 & is headquartered in Bagsvaerd, Denmark. Novo Nordisk A/S, together with its subsidiaries, engages in research & development, manufacture, & distribution of pharmaceutical products in Europe, Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, & internationally. It operates in two segments, Diabetes & Obesity Care, & Rare Disease. Diabetes & Obesity care segment provides products for diabetes, obesity, cardiovascular, & other emerging therapy areas.
Rare Disease segment offers products in areas of rare blood disorders, rare endocrine disorders, & hormone replacement therapy. company also provides insulin pens, growth hormone pens, & injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens & Dose Check, insulin dose guidance application. The company has collaboration agreement with Aspen Pharmaceuticals to produce insulin products.
Novo Nordisk Similar Stocks
- 52 week high
- 19.95
- Market price
- 5.23 (0.19%)
- Volume
- 932817
- 3 Months Returns
- 137.73 %
- 6 Months Returns
- 185.79 %
- 1 Year Returns
- - 56.67 %
- 52 week high
- 6.47
- Market price
- 1.52 (-2.56%)
- Volume
- 25119
- 3 Months Returns
- - 16.48 %
- 6 Months Returns
- - 42.42 %
- 1 Year Returns
- 1.33 %
- 52 week high
- 45.92
- Market price
- 33.35 (-0.33%)
- Volume
- 7517082
- 3 Months Returns
- - 19.68 %
- 6 Months Returns
- - 25.86 %
- 1 Year Returns
- - 5.26 %
- 52 week high
- 2.95
- Market price
- 2.93 (324.64%)
- Volume
- 15179
- 3 Months Returns
- -
- 6 Months Returns
- -
- 1 Year Returns
- -
Frequently Asked Questions
What is the Novo Nordisk share price in India today?
Novo Nordisk share price is $105.27 as on 20 Nov 2024 09:30
What is the 52-Weeks High and Low Range of Novo Nordisk?
As on 20 Nov 2024 09:30, the 52-week high range for Novo Nordisk share is $148.15, while the low range is $94.73 for Novo Nordisk.
What are the historical returns of Novo Nordisk?
The historical returns if you invest in Novo Nordisk shares will be $105.27.
How can I purchase Novo Nordisk shares in India?
5paisa has collaborated with Vested to give its customers Zero Commission investing in US markets. Simply follow the steps given on this link.
Can fractional shares of Novo Nordisk shares be purchased?
Yes, with 5paisa you can purchase Novo Nordisk fractional shares or any other US company shares.
What are the documents required to start investing in Novo Nordisk stocks?
To invest in Novo Nordisk NVO you will need an image of your PAN card, and proof of address (Aadhar card or latest bank statement). The whole process is paperless and can be completed in minutes.
Who is Chief Executive Officer (CEO) of Novo Nordisk A/S (NVO)?
Mr Jørgensen joined Novo Nordisk in 1991 as economist in Health Care, Economy & Planning & has over years completed overseas postings in Netherlands, US & Japan. In 2004 he was appointed senior vice president for IT & Corporate Development. In January 2013 he was appointed executive vice president & chief information officer assuming responsibility for IT, Quality & Corporate Development. In November 2014 he took over responsibilities for Corporate People & Organisation & Business Assurance & became chief of staff. Mr Jørgensen was appointed president & chief executive officer in January 2017.